Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

  • Brief Report
  • Published:
Archives of Virology Aims and scope Submit manuscript

This article was retracted on 13 February 2024

This article has been updated

Abstract

The aim of this work was assessment of the efficacy and tolerability of two different regimens for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based therapy. This prospective study included 104 HCV patients who failed to respond to SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and tolerability were assessed. The 12-week sustained virological response (SVR12) rates were 96% and 94.4% in groups B and A, respectively, with no significant difference (p = 1.000). Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.

ClinicalTrials.gov identifier: NCT02992457.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Change history

  • 28 August 2023

    Editor's Note: Readers are alerted that concerns have been raised about the reporting of this clinical trial. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.

  • 13 February 2024

    This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1007/s00705-024-05990-z

References

  1. Andrea L (2015) Global control of hepatitis C virus. Science 349:790–791

    Article  Google Scholar 

  2. Jefferies M, Rauff B, Rashid H et al (2018) Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 6(13):589–599

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ahmed OA, Kaisar HH, Badawi R et al (2018) Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 1(11):295–298

    Article  Google Scholar 

  4. Ahmed OA, Elsebaey MA, Fouad MHA et al (2018) Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist 28(11):441–445

    Article  Google Scholar 

  5. Ahmed OA, Safwat E, Khalifa MO et al (2018) Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol 2018:9616234

    Article  PubMed  PubMed Central  Google Scholar 

  6. Abd-Elsalam S, Badawi R, Elnawasany S et al (2018) Sofosbuvir, pegylated interferon and ribavirin in treatment of an Egyptian cohort with hepatitis C virus infection in real life clinical practice. Infect Disord Drug Targets. https://doi.org/10.2174/1871526518666180912121835(Epub ahead of print)

    Article  PubMed  Google Scholar 

  7. Li H, Lo S (2015) Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol 7(10):1377–1389

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pawlotsky J, Aghemo A, Back D, Dusheiko G, Forns X, Negro F et al (2016) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 65(3):457–656

    Google Scholar 

  9. Jesudian A, Gelwan M, Jacobson I (2012) Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol 8(2):91–101

    Google Scholar 

  10. Asselah T, Marcellin P, Schinazi R (2018) Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int 38(Suppl. 1):7–13

    Article  PubMed  PubMed Central  Google Scholar 

  11. El-Akel W, El-Sayed M, El Kassas M, El-Serafy M, Khairy M, Elsaeed K et al (2017) National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat 24(4):262–267

    Article  CAS  PubMed  Google Scholar 

  12. Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H et al (2017) Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18,378 patients in Egypt. Aliment Pharmacol Ther 47(3):421–431

    Article  PubMed  Google Scholar 

  13. Hassany M, Elsharkawy A (2017) Advances in treatment of hepatitis C and B; chap. 6: HCV treatment failure in the era of DAAs, IntechOpen, pp 117–128

  14. Sharafi H, Alavian S (2018) Hepatitis C resistance to NS5A inhibitors: is it going to be a problem? World J Hepatol 10(9):543–548

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pawlotsky J, Negro F, Aghemo A, Marina M, Dalgard O, Dusheiko G et al (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511

    Article  Google Scholar 

  16. AASLD-IDSA HCV Guidance: recommendations for testing, managing, and treating hepatitis C. [Online 05 Oct. 2018]

  17. Supreme Council and NCCVH Hepatitis C Updated Treatment Protocol (2016) Egyptian National Committee for the Control of Viral Hepatitis

  18. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services 2017

  19. Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M (2018) Retreatment efficacy of sofosbuvir/ombitasvir/paritaprevir/ ritonavir + ribavirin for hepatitis C virus genotype 4 patients. Dig Dis Sci 63(5):1341–1347

    Article  CAS  PubMed  Google Scholar 

  20. El Kassas M, Alboraie M, Mostafa A, Ezzat R, El Tahan A, Afify S et al (2017) After successful hepatitis C virus antiviral therapy: it looks that normal alanine aminotransferase level is not the normal. J Clin Lab Anal 38:e22296

    Google Scholar 

  21. Bourliere M, Gordon S, Flamm S, Cooper C, Ramji A, Tong M et al (2017) Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376(22):2134–2146

    Article  CAS  PubMed  Google Scholar 

  22. Ledinghen V, Anne V, Jose U, Lucia P, Baptiste H, Giovanna S et al (2018) Sofosbuvir + glecaprevir/pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate use. J Hepatol 68:S259

    Article  Google Scholar 

  23. Gane J, Shiffman L, Etzkorn K, Morelli G, Stedman M, Davis MN et al (2017) Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology 66(4):1083–1089

    Article  CAS  PubMed  Google Scholar 

  24. Hèzode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Alias M et al (2016) Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 63(6):1809–1816

    Article  PubMed  Google Scholar 

  25. Lawitz E, Flamm S, Yang C, Pang S, Zhu Y, Svarovskaia E et al (2015) Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol 62:S192

    Article  Google Scholar 

  26. Sulkowski M, Feld J, Lawitz E, Felizarta F, Corregidor M, Khalid O et al (2018) Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. J Viral Hepat 6:631–639

    Article  Google Scholar 

Download references

Acknowledgements

The authors especially thank professor Mohammad Safi Ullah and professor Ayman Mohammed Abdou Elguindy for their guidance and encouragement in this work.

Author information

Authors and Affiliations

  1. Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University, Benha, Egypt

    Ebada Mohamed Said, Badawy A. Abdulaziz & Ibrahim Hussein El Attar

  2. Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt

    Mohamed El Kassas

  3. National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt

    Mohammed Emadeldeen

  4. Tropical Medicine Department, Tanta University, Tanta, Egypt

    Sherief M. Abd-Elsalam

Authors
  1. Ebada Mohamed Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Badawy A. Abdulaziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed El Kassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ibrahim Hussein El Attar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammed Emadeldeen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sherief M. Abd-Elsalam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sherief M. Abd-Elsalam.

Ethics declarations

Conflict of interest

:The authors declare that there is no conflict of interest.

Informed consent

Participants provided written informed consent, and the study was approved by the institutional ethical committee.

Additional information

Handling Editor: Michael A. Purdy.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1007/s00705-024-05990-z

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Said, E.M., Abdulaziz, B.A., El Kassas, M. et al. RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol 165, 1633–1639 (2020). https://doi.org/10.1007/s00705-020-04639-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-020-04639-x

Search

Navigation